Status Epilepticus: Convulsive & Non-Convulsive

ABPN Neurocritical Care Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU

Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU

2 Chapter 2: Cerebral Physiology & Intracranial Dynamics

Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes

3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management

Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions

4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management

Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy

5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management

Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury

6 Chapter 6: Neuropharmacology, Analgesia & Sedation

ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU

7 Bleeding, Thrombosis & Hematologic Emergencies

Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity

8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine

Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention

9 Systemic Trauma & Environmental Injury

Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging

10 Cardiac Emergencies & Mechanical Support

IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies

11 Kidney Injury, Acid–Base & Renal Replacement

Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement

12 Systemic Infection & Endocrine Emergencies

Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies

13 Gastrointestinal & Hepatic Emergencies

Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects

14 Chapter 9: Neuroimaging in the Neuro-ICU

Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness

15 Chapter 10: Electrophysiology & Neuromonitoring

Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

16 Angiography, Electrodiagnosis & CSF Analysis

Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage

17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria

Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria

18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies

Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction

19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage

Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH

20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia

Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations

21 Venous, Spinal & Traumatic Vascular Disease

Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury

22 Chapter 15: Traumatic Brain & Spinal Cord Injury

Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes

23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies

Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure

24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis

Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies

25 Neuroinflammation & Neurooncology

Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies

26 Pregnancy, Transplantation & Pediatric Care

Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care

27 Chapter 18: Neurosurgical & Perioperative Emergencies

Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies

28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU

Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor

Status Epilepticus: Convulsive & Non-Convulsive

Key Takeaways Explain This Topic AI

Treat a continuing generalized convulsion at five minutes; simultaneous stabilization and glucose assessment must not delay an adequate benzodiazepine.

Escalate promptly after adequate initial treatment fails, using an appropriate IV antiseizure drug and cause-directed therapy.

ESETT found similar primary response rates with levetiracetam, fosphenytoin, and valproate; comorbidities guide selection.

ACNS distinguishes a ten-second electrographic seizure from status lasting at least ten continuous minutes or occupying at least 20% of an hour.

Persistent impaired consciousness after convulsions can require EEG to distinguish ongoing seizures from other causes.

Last updated: October 2026

Status Epilepticus: Convulsive & Non-Convulsive

Status epilepticus ( S E SE SE ) is among the most common and devastating neurological emergencies encountered in the neuro-intensive care unit, with an annual incidence of 10 to 40 per 100,000 and an in-hospital mortality reaching 15 – 20 % 15\text{--}20\% 15 – 20% . Successful management hinges on rapid, protocol-driven treatment that parallels the molecular progression of the condition from self-terminating network hypersynchrony to irreversible, pharmacoresistant excitotoxic injury.

Operational Definitions: The 2015 ILAE Classification ( t 1 t_1 t 1 ​ and t 2 t_2 t 2 ​ )

Historically, status epilepticus was defined as continuous seizure activity lasting ≥ 30 minutes \ge 30\text{ minutes} ≥ 30 minutes , or recurrent seizures without full interictal return to baseline neurological status. However, basic neurobiology and clinical trials revealed that waiting 30 minutes before initiating aggressive therapy results in severe pharmacoresistance and profound neuronal loss. In 2015, the International League Against Epilepsy ( I L A E ILAE I L A E ) established a conceptual and operational framework incorporating two distinct, semiology-specific timepoints:

Timepoint 1 ( t 1 t_1 t 1 ​ ): The time when a seizure has abnormally exceeded its physiological duration, indicating that endogenous mechanisms of seizure termination have failed. Treatment must be initiated immediately at t 1 t_1 t 1 ​ .

Timepoint 2 ( t 2 t_2 t 2 ​ ): The time of ongoing epileptic activity beyond which there is a substantial risk of long-term neuronal necrosis, network alteration, and functional deficit. Pharmacoresistance accelerates dramatically after t 2 t_2 t 2 ​ .

Seizure Semiology Operational Timepoint t 1 t_1 t 1 ​ (Initiate Treatment) Operational Timepoint t 2 t_2 t 2 ​ (Impending Neuronal Damage) Pathophysiologic Hallmarks

Generalized Convulsive SE (GCSE) 5 minutes 5\text{ minutes} 5 minutes 30 minutes 30\text{ minutes} 30 minutes Bilateral tonic-clonic motor convulsions, massive sympathetic surge followed by autonomic failure, lactic acidosis, and hyperthermia.

Focal SE with Impaired Awareness 10 minutes 10\text{ minutes} 10 minutes > 60 minutes > 60\text{ minutes} > 60 minutes Limbic or neocortical seizure networks; subtle automatisms, vegetative symptoms, and fluctuating cognitive impairment.

Absence Status Epilepticus 10 – 15 minutes 10\text{--}15\text{ minutes} 10 – 15 minutes Unknown (likely prolonged) Generalized 3 Hz 3\text{ Hz} 3 Hz spike-wave complexes, non-motor lethargy or waxing/waning stupor without primary cortical necrosis.

Important

Most generalized convulsive seizures terminate spontaneously within 1 to 2 minutes. Any convulsion continuing beyond 5 minutes ( t 1 t_1 t 1 ​ ) must be actively treated as status epilepticus. Waiting for 30 minutes before intervening is obsolete and directly causes secondary excitotoxic cortical injury.

Stabilization and Initial Benzodiazepine Therapy

The initial phase of status epilepticus requires immediate administration of a fast-acting, high-potency benzodiazepine to enhance synaptic G A B A A GABA_A G A B A A ​ receptor-mediated chloride conductances and terminate synchronous cortical depolarization.

IV lorazepam: 0.1 mg/kg, maximum 4 mg per dose, administered at an appropriate rate and repeatable once if seizures persist. Prepare airway and respiratory support; adequate treatment should not be withheld solely from fear of respiratory depression during ongoing convulsive status.

The Landmark RAMPART Trial (NEJM 2012)

The Rapid Anticonvulsant Medication Prior to Arrival Trial ( R A M P A R T RAMPART R A MP A RT ) evaluated 893 prehospital status epilepticus patients randomized to receive either intramuscular midazolam via autoinjector ( 10 mg 10\text{ mg} 10 mg ) or intravenous lorazepam ( 4 mg 4\text{ mg} 4 mg ). The trial established two paradigm-shifting findings:

Non-Inferiority & Superior Rapid Cessation: Intramuscular midazolam was statistically non-inferior and clinically superior in achieving rapid seizure cessation upon arrival in the emergency department ( 73.4 % 73.4\% 73.4% vs. 63.4 % 63.4\% 63.4% , p < 0.001 p < 0.001 p < 0.001 ).

The Paradox of Vascular Access: Although IV lorazepam has a faster onset once injected, establishing IV access in an actively convulsing patient requires an average of 4 to 8 minutes. Intramuscular administration eliminated this access delay, resulting in significantly faster overall time from paramedic arrival to medication delivery and seizure termination.

Warning

The Underdosing Pitfall: The single most common error in acute status epilepticus management is benzodiazepine underdosing (e.g., administering 1 mg 1\text{ mg} 1 mg or 2 mg 2\text{ mg} 2 mg of lorazepam to a 70 – 80 kg 70\text{--}80\text{ kg} 70 – 80 kg adult). Multiple underdosed boluses fail to terminate seizures, prolong t 1 t_1 t 1 ​ , and substantially increase the rates of respiratory depression and refractory status epilepticus.

Prompt Second-Line Therapy for Benzodiazepine-Refractory Status

Seizures persisting despite full, weight-appropriate first-line benzodiazepine administration enter Phase 2, termed Established Status Epilepticus ( E S E ESE ESE ) . Phase 2 demands immediate initiation of a non-sedating intravenous antiseizure medication ( A S M ASM A SM ) to prevent recurrence and suppress emerging pharmacoresistance.

The Landmark ESETT Trial (NEJM 2019)

For decades, fosphenytoin was empirically presumed superior for benzodiazepine-refractory SE. The landmark Established Status Epilepticus Treatment Trial ( E S E T T ESETT ESETT ) prospectively tested this assumption in a multicenter, randomized, double-blind, comparative-effectiveness trial of 384 children and adults with benzodiazepine-refractory convulsive SE lasting ≥ 5 minutes \ge 5\text{ minutes} ≥ 5 minutes :

Treatment Arms:

Levetiracetam: 60 mg/kg 60\text{ mg/kg} 60 mg/kg IV (maximum 4500 mg 4500\text{ mg} 4500 mg ) infused over 10 minutes.

Fosphenytoin: 20 mg PE/kg 20\text{ mg PE/kg} 20 mg PE/kg IV (maximum 1500 mg PE 1500\text{ mg PE} 1500 mg PE ) infused at 150 mg PE/min 150\text{ mg PE/min} 150 mg PE/min .

Sodium Valproate: 40 mg/kg 40\text{ mg/kg} 40 mg/kg IV (maximum 3000 mg 3000\text{ mg} 3000 mg ) infused over 10 minutes.

Primary Finding: The primary endpoint (cessation of status epilepticus and improvement in responsiveness at 60 minutes without rescue therapy) occurred in 47 % 47\% 47% of the levetiracetam group, 45 % 45\% 45% of the fosphenytoin group, and 46 % 46\% 46% of the valproate group. There were no statistically significant differences in efficacy among the three agents.

Safety Profile: No significant safety difference was demonstrated among the treatment groups; this does not prove identical risks in every patient.

Agent ESETT Dose & Infusion Rate Mechanism of Action Clinical Advantages Key Contraindications & Cautions

Levetiracetam 60 mg/kg 60\text{ mg/kg} 60 mg/kg IV (max 4500 mg 4500\text{ mg} 4500 mg ); Infuse over 10 min 10\text{ min} 10 min Binds synaptic vesicle protein 2A ( S V 2 A SV2A S V 2 A ), inhibiting exocytotic glutamate release Limited hepatic metabolism and few pharmacokinetic interactions; generally favorable cardiovascular tolerability Dose reduction mandatory in renal failure; risk of acute post-ictal agitation/psychosis

Fosphenytoin 20 mg PE/kg 20\text{ mg PE/kg} 20 mg PE/kg IV (max 1500 mg PE 1500\text{ mg PE} 1500 mg PE ); Infuse ≤ 150 mg PE/min \le 150\text{ mg PE/min} ≤ 150 mg PE/min Fast inactivation of voltage-gated sodium channels Water-soluble prodrug; has a lower local-injury risk than IV phenytoin, although serious local reactions are still possible; no propylene glycol vehicle Strictly contraindicated in second/third-degree AV block, severe bradycardia, or sinus arrest

Sodium Valproate 40 mg/kg 40\text{ mg/kg} 40 mg/kg IV (max 3000 mg 3000\text{ mg} 3000 mg ); Infuse over 10 min 10\text{ min} 10 min Blocks T-type C a 2 + Ca^{2+} C a 2 + channels, enhances GABA synthesis, voltage-gated N a + Na^+ N a + blockade Broad spectrum across all seizure semiologies; favorable hemodynamics Contraindicated in hepatic failure, pancreatitis, urea cycle defects, and mitochondrial disease ( P O L G POLG PO L G )

Lacosamide 200 – 400 mg 200\text{--}400\text{ mg} 200 – 400 mg IV bolus; Infuse over 5 – 10 min 5\text{--}10\text{ min} 5 – 10 min Selectively enhances slow inactivation of voltage-gated N a + Na^+ N a + channels Favorable drug interaction profile; highly effective second-line alternative Dose-dependent PR interval prolongation; caution in heart block or nodal dysfunction

Note

Because the ESETT trial demonstrated therapeutic equivalence, the choice among levetiracetam, fosphenytoin, and valproate is tailored to individual comorbidities: avoid fosphenytoin in conduction disease, avoid valproate in hepatic failure or mitochondrial disorders, and avoid levetiracetam in severe acute psychiatric distress.

Non-Convulsive Status Epilepticus (NCSE)

Non-convulsive status epilepticus ( N C S E NCSE NCSE ) is defined as a persistent state of electrographic seizure activity lasting ≥ 10 minutes \ge 10\text{ minutes} ≥ 10 minutes resulting in altered mental status or sensory/behavioral deficits without prominent bilateral convulsive motor movements. In the neuro-ICU, NCSE is diagnosed in 10 – 40 % 10\text{--}40\% 10 – 40% of patients with unexplained altered mental status following cardiac arrest, acute ischemic stroke, intracerebral hemorrhage, traumatic brain injury, or sepsis.

Clinical Presentation

NCSE presents subtly across a spectrum of encephalopathic findings:

• Unexplained coma or failure to awaken after convulsive status epilepticus or neurotrauma
• Fluctuating delirium, confusion, catatonia, or episodic mutism

Subtle motor "micro-signs": micro-clonus of the eyelids, subtle facial twitching, rhythmic nystagmus or ocular deviation, and continuous perioral automatisms

EEG Diagnosis Requires Duration and Context

Under ACNS 2021 terminology, an electrographic seizure includes epileptiform discharges averaging more than 2.5 Hz for at least ten seconds or a pattern with definite evolution lasting at least ten seconds. Electrographic status is at least ten continuous minutes of seizure or seizures occupying at least 20% of any sixty-minute period. One ten-second seizure is not automatically status epilepticus. Clinical correlates and electroclinical responses to medication can add important evidence. Ictal-interictal continuum patterns do not all require anesthetic coma.

The AES convulsive algorithm describes stabilization during 0–5 minutes, initial benzodiazepine treatment during 5–20 minutes, second therapy during 20–40 minutes, and further escalation after that. These are phase markers, not instructions to delay medication. Treat a continuing five-minute convulsion promptly, prepare the next agent while administering the benzodiazepine, and escalate when adequate initial therapy fails. Confirm that the drug was actually delivered and that glucose and other immediately reversible causes are addressed.

Source: AES guideline and ACNS 2021 terminology .